Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Other Non-Current Assets (2017 - 2025)

KalVista Pharmaceuticals' Other Non-Current Assets history spans 11 years, with the latest figure at $1.5 million for Q2 2025.

  • On a quarterly basis, Other Non-Current Assets rose 173.02% to $1.5 million in Q2 2025 year-over-year; TTM through Apr 2025 was $1.5 million, a 173.02% increase, with the full-year FY2025 number at $1.5 million, up 173.02% from a year prior.
  • Other Non-Current Assets hit $1.5 million in Q2 2025 for KalVista Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for KALV hit a ceiling of $1.5 million in Q2 2025 and a floor of $106000.0 in Q2 2023.
  • Historically, Other Non-Current Assets has averaged $553454.5 across 4 years, with a median of $397000.0 in 2024.
  • Biggest five-year swings in Other Non-Current Assets: grew 4.62% in 2021 and later skyrocketed 470.75% in 2024.
  • Tracing KALV's Other Non-Current Assets over 4 years: stood at $200000.0 in 2021, then skyrocketed by 68.5% to $337000.0 in 2023, then skyrocketed by 309.2% to $1.4 million in 2024, then rose by 12.26% to $1.5 million in 2025.
  • Business Quant data shows Other Non-Current Assets for KALV at $1.5 million in Q2 2025, $1.4 million in Q4 2024, and $662000.0 in Q4 2024.